Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
R3I EVENTS
24 November, Chantilly, France
New Joint Initiative of the
International Atherosclerosis Society (IAS) and Residual Risk Reduction Initiative (R3i)
on the concept of SPPARM-a
View the agenda..
R3i editorial
6 November 2018

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Residual cardiovascular risk: triglyceride metabolism and genetics provide a key Read more...

Understanding the major contributors to residual cardiovascular risk has been a tedious business. With the failure of major studies such as AIM-HIGH with niacin, and dal-OUTCOMES and ACCELERATE with the cholesteryl ester transfer protein inhibitors dalcetrapib and evacetrapib, the relevance of high-density lipoprotein cholesterol (HDL-C) has been consigned to history. Instead, researchers have refocused their attention on triglycerides (TG), given long-standing evidence for an association with increased risk for cardiovascular disease (CVD). However, as TG are metabolized by most cells in the body, it is what they represent that is most relevant....
landmark study
6 November 2018

News from CANTOS: Modulation of the interleukin-6 signalling pathway reduces cardiovascular eventsRead more...

The CANTOS study was widely regarded as a landmark study providing proof of concept evidence for chronic subclinical inflammation as a modifiable contributor to residual cardiovascular risk, independent of lipid lowering.1 There is, however, also strong circumstantial evidence for a role for IL-6, which is...
focus on...
6 November 2018

More evidence linking remnants with cardiovascular diseaseRead more...

The association of TG with cardiovascular risk has long been recognized.1,2 TG are, however, merely surrogates for TG-rich lipoproteins and their remnants.3,4 and there is now strong evidence, largely provided by genetic studies, that these intermediate and residual particles of TG metabolism, notably remnant lipoproteins...
recent publication

News flash: REDUCE-IT meets primary endpointRead more...

Topline results of the REDUCE-IT trial show that high doses (4-g daily) of eicosapentaenoic acid (EPA) led to a 25%...
recent publication

A link between elevated triglycerides and risk for peripheral artery revascularization?Read more...

Evidence from a retrospective study, presented at the 2018 European Society of Cardiology Congress, Munich, Germany supports a possible link...
recent publication

Elevated triglycerides contribute to residual cardiovascular riskRead more...

Despite well controlled low-density lipoprotein cholesterol (LDL-C) levels on statin treatment, individuals with elevated triglycerides are at high residual risk,...
recent publication

Triglycerides predict first cardiovascular events in diabetesRead more...

Findings from the standard versus intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY) study implicate serum triglycerides as...
recent publication

Novel variant for high triglycerides in Arab populationRead more...

Global studies which aim to identify the genetic basis of variation in blood lipid traits and extreme lipid phenotypes have...
recent publication

Non-alcoholic fatty liver disease predicts coronary artery disease Read more...

In metabolically healthy individuals, the presence of non-alcoholic fatty liver disease (NAFLD) was independently associated with coronary artery calcification, according...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARĪ±Ms in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.